PacBio RS Data to Validate SNPs Called from Illumina Sequencing?

Would you have thought that PacBio RS sequences with about 15% single read error rate can outdo MiSeq reads in validation of the variants called by WGS or Exome Sequencing? Personally, I wouldn’t have thought so. But the study of the Broad Institute published a few days ago clearly shows that they can.

Variants called within projects that aim at analysis of variants definitely need validation to determine the rate at which the mutations have been correctly called and to confirm the specific reported changes. Currently used techniques like Sequenom genotyping and Sanger sequencing provide essential drawbacks, such as the need for manual interpretation or low data throughput. For that reason, Carneiro and his colleagues studied the power of PacBio RS and MiSeq data as a validation tool and compared the results with each other.

They generated amplicons covering 98 variants called in the 1000 Genomes Project and sequenced the PCR products with both instruments, PacBio RS and MiSeq. Using PacBio RS data 96 out of the 98 variants could be correctly genotyped, whereas the MiSeq correctly genotyped only 93 sites. The explanation of the authors is quite simple: The completely random distribution of errors across the reads can overcome the low read accuracy problem if sufficient coverage is applied.

Manual checking of the sites, that were miscalled using the PacBio dataset, revealed, that one of the two miscalls happened due to a reference bias (true variation is hidden). Such bias is introduced by alignment parameters where the gap open penalty is higher than the base mismatch penalty. The high error rate of PacBio RS reads makes these parameters necessary.

However, Carneiro told GenomeWeb, that the researchers are not using a different aligner that was developed at the Broad Institute. This aligner re-aligns the reads using different parameters and therefore reduces the problem to a great extent.

For me the study shows that there is potential for PacBio RS sequencing. Nevertheless, like the variants, also this study result needs to be validated. Furthermore I think that the value of the study needs also to be seen in relation to the sequencing cost for both instruments. While the consumable prices for both techniques are in a similar range, the several fold higher cost for the PacBio RS instrument makes a remarkable difference.

Regina Dick

About Regina Dick

Regina is a driving supporter of next generation sequencing activities.

No comments yet... Be the first to leave a reply!